I C U Medical Inc (ICUI) 125.47 $ICUI Shares of

I C U Medical Inc (ICUI) 125.47 $ICUI

Shares of ICUI Up 25.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Sep 01, 1:33PM CDT
SmarTrend identified an Uptrend for ICU Medical (NASDAQ:ICUI) on March 21st, 2016 at $99.62. In approximately 5 months, ICU Medical has returned 25.13% as of today's recent price of $124.65.
ICUI: 125.47 (+0.26)

ICU Medical Reaches Analyst Target Price
ETFChannel.com - Wed Aug 10, 6:38AM CDT
In recent trading, shares of ICU Medical, Inc. have crossed above the average analyst 12-month target price of $124.00, changing hands for $126.32/share.
ICUI: 125.47 (+0.26)

SmarTrend Watching for Potential Pullback in Shares of ICU Medical After 7.15% Gain
Comtex SmarTrend(R) - Tue Aug 09, 4:26PM CDT
ICU Medical (NASDAQ:ICUI) traded in a range yesterday that spanned from a low of $119.28 to a high of $128.93. Yesterday, the shares gained 7.1%, which took the trading range above the 3-day high of $118.31 on volume of 166,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ICUI: 125.47 (+0.26)

Here's 5 Medical Stocks Soaring After Earnings Today
Ryan McQueeney - Zacks Investment Research - Tue Aug 09, 1:36PM CDT
Check out these five medical-related companies that are in the green following their most recent reports.
ENDP: 20.54 (+0.31), ICUI: 125.47 (+0.26), VRX: 29.19 (+0.07), OPK: 9.28 (-0.01), NVRO: 96.56 (+0.54)

ICU Medical, Inc. Announces Second Quarter 2016 Results
GlobeNewswire - Mon Aug 08, 3:05PM CDT
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced financial results for the second quarter ended June 30, 2016.
ICUI: 125.47 (+0.26)

Medical Product Stocks' Earnings on Aug 8: NVRO, ICUI & More
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 6:40AM CDT
The Q2 results so far portrayed a better picture compared to the last two quarters.
ICUI: 125.47 (+0.26), ZLTQ: 38.09 (-0.12), AXDX: 22.37 (+0.37), NVRO: 96.56 (+0.54)

FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 6:31AM CDT
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, the FDA go-ahead will expand Medtronic's (MDT) footprint in the billion-dollar neurosurgical market.
ICUI: 125.47 (+0.26), MDT: 87.63 (+0.65), BAX: 46.10 (-0.08), LMAT: 18.11 (+0.35)

Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 125.47 (+0.26), BAX: 46.09 (-0.09), LMAT: 18.11 (+0.35), HOLX: 38.56 (+0.10)

Hill-Rom Introduces VisiVest, First Connected Airways System
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:19AM CDT
Hill-Rom Holdings, Inc. (HRC) recently launched VisiVest System, the world's first wirelessly connected airway clearance system.
ICUI: 125.47 (+0.26), LMAT: 18.11 (+0.35), NUVA: 66.37 (+0.31), HRC: 59.84 (+0.59)

Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 125.47 (+0.26), BAX: 46.09 (-0.09), LMAT: 18.11 (+0.35), HOLX: 38.56 (+0.10)

Bruker Well Poised on Product Innovation amid Currency Woes
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 6:23AM CDT
On Jun 14, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR).
ICUI: 125.47 (+0.26), LMAT: 18.11 (+0.35), BRKR: 22.34 (-0.10), NUVA: 66.37 (+0.31)

Boston Scientific: Restructuring Plan, Global Growth Impress
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 6:14AM CDT
On Jun 13, 2016, we issued an updated research report on Boston Scientific Corporation (BSX).
BSX: 24.18 (-0.15), ICUI: 125.47 (+0.26), BAX: 46.09 (-0.09), LMAT: 18.11 (+0.35)

PetMed Remains Strong on New Order & Reorder Sales Gain
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 10:15AM CDT
On Jun 13, 2016, we issued an updated research report on PetMed Express (PETS).
ICUI: 125.47 (+0.26), PETS: 20.39 (+0.20), LMAT: 18.11 (+0.35), NUVA: 66.37 (+0.31)

Zimmer Biomet's Spine Business to Get a Boost with LDR Buy
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:00AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) has entered into a definitive agreement to acquire LDR Holding Corp. (LDRH) for a total deal value of $1 billion.
BSX: 24.18 (-0.15), ICUI: 125.47 (+0.26), ZBH: 129.28 (+0.93), LDRH: 36.98 (-0.02)

NuVasive to Strengthen Spine Service Line with Biotronic Buy
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:17AM CDT
NuVasive, Inc. (NUVA) recently entered into a definitive agreement to acquire privately held Biotronic NeuroNetwork.
BSX: 24.18 (-0.15), ICUI: 125.47 (+0.26), BAX: 46.09 (-0.09), NUVA: 66.37 (+0.31)

Abaxis (ABAX): Solid Veterinary Show Despite Global Hiccups
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:01AM CDT
On Jun 3, 2016, we issued an updated research report on Abaxis, Inc. (ABAX). The stock currently carries a Zacks Rank #4 (Sell).
ICUI: 125.47 (+0.26), ABAX: 50.15 (-0.25), LMAT: 18.11 (+0.35), NUVA: 66.37 (+0.31)

Medtronic (MDT) Posts Solid Q4; Covidien Synergy Continues
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 6:31AM CDT
On Jun 3, 2016, we issued an updated research report on Medtronic plc (MDT).
BSX: 24.18 (-0.15), ICUI: 125.47 (+0.26), MDT: 87.63 (+0.65), LMAT: 18.11 (+0.35)